

August 2014

An NIH SBIR grant (1R43CA177002) has been awarded to Provid Pharmaceuticals by the National Cancer Institute to develop second-generation analogs for the imipridone class of anticancer agents being developed by Oncoceutics, Inc.

The lead molecule, discovered by co-PI Wafik El-Deiry and his team at Penn State Hershey Medical Center, is exemplified by ONC201. Provid will perform medicinal chemistry studies to develop structure-activity relationships and to identify optimized drug candidates within the compound class. Biological studies will be performed by Dr. El-Deiry's lab.